Analytical Data
-
基因名
BNIPL
- Application
-
别名
BNIPL; Bcl-2/adenovirus E1B 19 kDa-interacting Protein 2-like Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q7Z465
-
表达区间
1-357aa
-
氨基酸序列
MGTIQEAGKK TDVGVREIAE APELGAALRH GELELKEEWQ DEEFPRLLPE EAGTSEDPED PKGDSQAAAG TPSTLALCGQ RPMRKRLSAP ELRLSLTKGP GNDGASPTQS APSSPDGSSD LEIDELETPS DSEQLDSGHE FEWEDELPRA EGLGTSETAE RLGRGCMWDV TGEDGHHWRV FRMGPREQRV DMTVIEPYKK VLSHGGYHGD GLNAVILFAS CYLPRSSIPN YTYVMEHLFR YMVGTLELLV AENYLLVHLS GGTSRAQVPP LSWIRQCYRT LDRRLRKNLR ALVVVHATWY VKAFLALLRP FISSKFTRKI RFLDSLGELA QLISLDQVHI PEAVRQLDRD LHGSGGT
-
分子量
39 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BNIPL (Bone marrow Niches Influencing Protein-like), a relatively novel recombinant protein, has garnered significant attention in recent years due to its potential role in hematopoiesis and the regulation of bone marrow microenvironments. Research indicates that BNIPL exhibits a unique interaction with hematopoietic stem cells (HSCs) and stromal cells, suggesting that it may influence stem cell niches critical for blood cell development. Understanding the molecular mechanisms through which BNIPL functions could shed light on various blood disorders and malignancies, such as leukemia and lymphoma, where the bone marrow microenvironment is often disrupted. The reconstitution and characterization of BNIPL also offer insights into its therapeutic potential, given its possible role in enhancing HSC mobilization and engraftment during transplantation procedures. Furthermore, studies have indicated its involvement in modulating inflammatory responses within the bone marrow, providing a link between immunology and hematology. Consequently, ongoing research aims to elucidate the comprehensive biological functions of BNIPL, paving the way for its applications in regenerative medicine and targeted therapies for blood-related illnesses, ultimately improving patient outcomes in hematological disorders.
